Drug intelligence / Profile preview

stedutumab

Development stage: Unknown
Lead developer: Jilin Province People's Hospital
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Stedutumab is a monoclonal antibody developed for the treatment of severe tetanus. It acts by specifically binding to and neutralizing tetanospasmin, the potent neurotoxin secreted by *Clostridium tetani*. By neutralizing the toxin before it enters the nervous system, stedutumab aims to mitigate the characteristic muscle spasms, seizures, and autonomic instability associated with the disease. It is currently being investigated in clinical trials, including a Phase 0 study in China (ChiCTR2500111942), as a potentially more potent or standardized alternative to human tetanus immunoglobulin (HTIG) for patients with high-grade tetanus (Ablett grade III–IV).

Other names: Stedutumabtetanus monoclonal antibody

Beyond the preview

Go deeper on stedutumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on stedutumab.

Explore the full profile